Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of tissue-agnostic approvals on management of primary brain tumors.

Trends in cancer - 1 Mar 2024

Ahluwalia Manmeet S, Khosla Atulya A, Ozair Ahmad, Gouda Mohamed A, Subbiah Vivek

Abstract excerpt

Novel tissue-agnostic therapeutics targeting driver mutations in tumor cells have been recently approved by FDA, driven by basket trials that have demonstrated their efficacy and safety across diverse tumor histology. However, the relative rarity of primary brain tumors (PBTs) has limited their representation in early trials of tissue-agnostic medications. Thus, consensus continues to evolve regarding utility of...

Read the complete abstract on PubMed

Topics

Humans
Mutation
Colorectal Neoplasms
Prognosis
Brain Neoplasms
Neoplastic Syndromes, Hereditary

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38245379
DOI: 10.1016/j.trecan.2023.11.005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of tissue-agnostic approvals on management of primary brain tumors.PMID 38245379Read ↗

Impact of tissue-agnostic approvals for patients with gastrointestinal malignanciesSemantic proximity Read ↗

Molecular matched targeted therapies for primary brain tumors-a single center retrospective analysis.Semantic proximity Read ↗

Target-Driven Tissue-Agnostic Drug Approvals; a New Path of Drug DevelopmentSemantic proximity Read ↗

Harnessing tumor-agnostic biomarkers for precision medicine in lymphoma.Semantic proximity Read ↗

[Histology-agnostic tumor treatment - a farewell to tumor entities?]Semantic proximity Read ↗

Next generation neuro-oncology.Semantic proximity Read ↗

NTRK gene fusions in solid tumors: agnostic relevance, prevalence and diagnostic strategiesSemantic proximity Read ↗

Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group.Semantic proximity Read ↗

Genomic medicine advances for brain tumors.Semantic proximity Read ↗

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors.Semantic proximity Read ↗

Tissue-Agnostic Drug Development: A New Path to Drug ApprovalSemantic proximity Read ↗

First Tissue-Agnostic Drug Approval IssuedSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.